Von Hippel-Lindau gene promoter (VHL promoter)

The Von Hippel-Lindau (VHL) gene promoter is a critical regulatory DNA sequence located on chromosome 3p25.3 that controls the expression of the VHL tumor suppressor protein [UniProt P40337]. This promoter contains a dense CpG island that, under normal physiological conditions, remains unmethylated to allow for the constitutive expression of VHL, which is essential for the oxygen-dependent degradation of Hypoxia-Inducible Factor (HIF) subunits [NCBI Gene ID: 7428]. In approximately 10-20% of sporadic clear cell renal cell carcinomas (ccRCC), the VHL promoter becomes pathologically hypermethylated, leading to epigenetic silencing of the gene [Herman et al., PNAS 1994]. This loss of VHL function results in the stabilization of HIF-1 alpha and HIF-2 alpha, triggering a pseudo-hypoxic response that promotes angiogenesis, metabolic reprogramming, and tumor progression [Maxwell et al., Nature 1999]. Therapeutic interventions targeting the VHL promoter primarily involve the use of DNA methyltransferase inhibitors like Decitabine to induce demethylation and reactivate gene expression [NCI Drug Dictionary]. Additionally, experimental epigenetic editing tools like CRISPR-dCas9 systems are being developed to specifically modify the promoter's epigenetic state without global effects [PubMed: 27112565]. Restoring VHL expression through promoter modulation represents a strategy to re-establish normal HIF regulation and suppress oncogenic signaling in VHL-silenced tumors.

Other names

VHL promoter regionVon Hippel-Lindau tumor suppressor promoterVHL 5' regulatory region

Inhibition of DNA methyltransferases (DNMTs) to reverse hypermethylation of CpG islands within the promoter, thereby restoring the expression of the VHL tumor suppressor protein [NCI Drug Dictionary].